Pulmonary arterial hypertension in breast cancer patients on HER2-targeted therapy: a review of FDA Adverse Events Reporting System data

This letter highlights a rare association of anti-HER2 cancer therapy with development of pulmonary arterial hypertension, based on a review of data from the FDA https://bit.ly/2X90xDu

Detalles Bibliográficos
Autores principales: Umoru, Godsfavour, Taitano, Matthew, Beshay, Sarah, Niravath, Polly, Sahay, Sandeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Original Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369436/
https://www.ncbi.nlm.nih.gov/pubmed/32714960
http://dx.doi.org/10.1183/23120541.00199-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369436/
https://www.ncbi.nlm.nih.gov/pubmed/32714960
http://dx.doi.org/10.1183/23120541.00199-2020

Ejemplares similares